AnaptysBio (ANAB) vs UroGen Pharma (URGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
AnaptysBio (ANAB) has outperformed UroGen Pharma (URGN) over the past year, gaining 76.6% versus a gain of 6.9%. Over five years, URGN leads with a +127.8% price change compared with +124.8% for ANAB. AnaptysBio is the larger company by market cap ($1.39 billion vs $1.36 billion), about 1.0 times the size.
On valuation, AnaptysBio trades at a lower forward P/E (8.7x vs 11.1x for UroGen Pharma). AnaptysBio converts more of its revenue into profit, with a net margin of -5.6% versus -139.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANAB | URGN |
|---|---|---|
| Share price | $46.63 | $27.65 |
| Market cap | $1.39B | $1.36B |
| 1-day change | -1.62% | -12.86% |
| YTD return | +44.28% | +18.06% |
| 1-year return | +76.58% | +6.88% |
| 5-year return | +124.76% | +127.76% |
| P/E ratio (TTM) | 7.15 | — |
| Forward P/E | 8.66 | 11.08 |
| EPS (TTM) | $6.52 | $-1.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $234.60M | $109.79M |
| Revenue growth (YoY) | +157.01% | +21.45% |
| Net income (latest FY) | $-13.23M | $-153.49M |
| Gross margin | — | 88.66% |
| Operating margin | 96.72% | -113.73% |
| Net margin | -5.64% | -139.81% |
| 52-week high | $72.36 | $50.81 |
| 52-week low | $26.01 | $16.50 |
| Distance from 52-week high | -35.56% | -45.58% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +87.11% | +119.57% |
| Average volume | 496.92K | 1.11M |
| Shares outstanding | 29.73M | 49.05M |
| Employees | — | 300 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANAB has outperformed URGN by 69.7 percentage points over the past year.
- AnaptysBio is more profitable, keeping -5.6 cents of every revenue dollar as net income versus -139.8 cents for UroGen Pharma.
- AnaptysBio grew revenue faster in its latest fiscal year (+157.01% vs +21.45%).
About AnaptysBio
ANAB stock →AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations
About UroGen Pharma
URGN stock →UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 300 employees
ANAB vs URGN FAQ
Which is bigger, AnaptysBio or UroGen Pharma?
AnaptysBio (ANAB) is larger, with a market capitalization of $1.39B compared with $1.36B for UroGen Pharma (URGN).
Which stock has performed better over the past year, ANAB or URGN?
ANAB returned +76.58% over the past 12 months, compared with +6.88% for URGN (price return, excluding dividends). Past performance does not predict future results.
Are AnaptysBio and UroGen Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.